Small-molecule inhibitors of lethal factor protease activity protect against anthrax infection

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4139-4145

  Moayeri, Mahtab ^a   Crown, Devorah ^a   Jiao, Guan Sheng ^b   Kim, Seongjin ^b   Johnson, Alan ^b   Leysath, Clinton ^a   Leppla, Stephen H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b PanThera Biopharma LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; LETHAL GENE INHIBITOR; NEUTRALIZING ANTIBODY; PROTEIN INHIBITOR; PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL SPORE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; EDEMA; ENZYME ACTIVITY; FEMALE; LETHAL GENE; LETHALITY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SURVIVAL;

ANIMALS; ANTHRAX; ANTI-BACTERIAL AGENTS; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; DRUG ADMINISTRATION SCHEDULE; FEMALE; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; PROTEASE INHIBITORS; SPORES, BACTERIAL; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84882348540     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00941-13     Document Type: Article

References (38)

1. Moayeri M, Leppla SH. 2009. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol. Aspects Med. 30:439-455.
2. Vitale G, Bernardi L, Napolitani G, Mock M, Montecucco C. 2000. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 352:739-745.
3. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD, Vande Woude GF. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737.
4. Hellmich KA, Levinsohn JL, Fattah R, Newman ZL, Maier N, Sastalla I, Liu S, Leppla SH, Moayeri M. 2012. Anthrax lethal factor cleaves mouse Nlrp1b in both toxin-sensitive and toxin-resistant macrophages. PLoS One 7:e49741. doi:10.1371/journal.pone.0049741.
5. Levinsohn JL, Newman ZL, Hellmich KA, Fattah R, Getz MA, Liu S, Sastalla I, Leppla SH, Moayeri M. 2012. Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLoS Pathog. 8:e1002638. doi:10.1371/journal.ppat.1002638.
6. Moayeri M, Sastalla I, Leppla SH. 2012. Anthrax and the inflammasome. Microbes Infect. 14:392-400.
7. Moayeri M, Crown D, Newman ZL, Okugawa S, Eckhaus M, Cataisson C, Liu S, Sastalla I, Leppla SH. 2010. Inflammasome sensor Nlrp1bdependent resistance to anthrax is mediated by caspase-1, IL-1 signaling and neutrophil recruitment. PLoS Pathog. 6:e1001222. doi:10.1371/journal.ppat.1001222.
8. Tournier JN, Rossi PS, Quesnel-Hellmann A, Baldari CT. 2009. Anthrax toxins: a weapon to systematically dismantle the host immune defenses. Mol. Aspects Med. 30:456-466.
9. Dumetz F, Jouvion G, Khun H, Glomski IJ, Corre JP, Rougeaux C, Tang WJ, Mock M, Huerre M, Goossens PL. 2011. Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax. Am. J. Pathol. 178:2523-2535.
10. Liu S, Miller-Randolph S, Crown D, Moayeri M, Sastalla I, Okugawa S, Leppla SH. 2010. Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice. Cell Host Microbe 8:455-462.
11. Firoved AM, Miller GF, Moayeri M, Kakkar R, Shen Y, Wiggins JF, McNally EM, Tang WJ, Leppla SH. 2005. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am. J. Pathol. 167:1309-1320.
12. Moayeri M, Haines D, Young HA, Leppla SH. 2003. Bacillus anthracis lethal toxin induces TNF-independent hypoxia-mediated toxicity in mice. J. Clin. Invest. 112:670-682.
13. Moayeri M, Crown D, Dorward DW, Gardner D, Ward JM, Li Y, Cui X, Eichacker P, Leppla SH. 2009. The heart is an early target of anthrax lethal toxin in mice: a protective role for neuronal nitric oxide synthase (nNOS). PLoS Pathog. 4:e1000456. doi:10.1371/journal.ppat.1000456.
14. Liu T, Milia E, Warburton RR, Hill NS, Gaestel M, Kayyali US. 2012. Anthrax lethal toxin disrupts the endothelial permeability barrier through blocking p38 signaling. J. Cell. Physiol. 227:1438-1445.
15. Warfel JM, Steele AD, D'Agnillo F. 2005. Anthrax lethal toxin induces endothelial barrier dysfunction. Am. J. Pathol. 166:1871-1881.
16. Hicks CW, Li Y, Okugawa S, Solomon SB, Moayeri M, Leppla SH, Mohanty A, Subramanian GM, Mignone TS, Fitz Y, Cui X, Eichacker PQ. 2011. Anthrax edema toxin has cAMP-mediated stimulatory effects and high-dose lethal toxin has depressant effects in an isolated perfused rat heart model. Am. J. Physiol.Heart Circ. Physiol. 300:H1108-H1118.
17. Kuo SR, Willingham MC, Bour SH, Andreas EA, Park SK, Jackson C, Duesbery NS, Leppla SH, Tang WJ, Frankel AE. 2008. Anthrax toxininduced shock in rats is associated with pulmonary edema and hemorrhage. Microb. Pathog. 44:467-472.
18. Lawrence WS, Marshall JR, Zavala DL, Weaver LE, Baze WB, Moen ST, Whorton EB, Gourley RL, Peterson JW. 2011. Hemodynamic effects of anthrax toxins in the rabbit model and the cardiac pathology induced by lethal toxin. Toxins (Basel) 3:721-736.
19. Sweeney DA, Cui X, Solomon SB, Vitberg DA, Migone TS, Scher D, Danner RL, Natanson C, Subramanian GM, Eichacker PQ. 2010. Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines. J. Infect. Dis. 202:1885-1896.
20. Watson LE, Kuo SR, Katki K, Dang T, Park SK, Dostal DE, Tang WJ, Leppla SH, Frankel AE. 2007. Anthrax toxins induce shock in rats by depressed cardiac ventricular function. PLoS One 2:e466. doi:10.1371/journal.pone.0000466.
21. Ha SD, Ng D, Lamothe J, Valvano MA, Han J, Kim SO. 2007. Mitochondrial proteins Bnip3 and Bnip3L are involved in anthrax lethal toxininduced macrophage cell death. J. Biol. Chem. 282:26275-26283.
22. Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD. 2009. Raxibacumab for the treatment of inhalational anthrax. N. Engl. J. Med. 361:135-144.
23. Jiao GS, Kim S, Moayeri M, Cregar-Hernandez L, McKasson L, Margosiak SA, Leppla SH, Johnson AT. 2010. Antidotes to anthrax lethal factor intoxication. 1. Discovery of potent lethal factor inhibitors with in vivo efficacy. Bioorg. Med. Chem. Lett. 20:6850-6853.
24. Jiao GS, Kim S, Moayeri M, Crown D, Thai A, Cregar-Hernandez L, McKasson L, Sankaran B, Lehrer A, Wong T, Johns L, Margosiak SA, Leppla SH, Johnson AT. 2012. Antidotes to anthrax lethal factor intoxication. 3. Evaluation of core structures and further modifications to the C2-side chain. Bioorg. Med. Chem. Lett. 22:2242-2246.
25. Kim S, Jiao GS, Moayeri M, Crown D, Cregar-Hernandez L, McKasson L, Margosiak SA, Leppla SH, Johnson AT. 2011. Antidotes to anthrax lethal factor intoxication. 2. Structural modifications leading to improved in vivo efficacy. Bioorg. Med. Chem. Lett. 21:2030-2033.
26. Leysath CE, Chen KH, Moayeri M, Crown D, Fattah R, Chen Z, Das SR, Purcell RH, Leppla SH. 2011. Mouse monoclonal antibodies to anthrax edema factor protect against infection. Infect. Immun. 79:4609-4616.
27. Pomerantsev AP, Sitaraman R, Galloway CR, Kivovich V, Leppla SH. 2006. Genome engineering in Bacillus anthracis using Cre recombinase. Infect. Immun. 74:682-693.
28. Corre JP, Piris-Gimenez A, Moya-Nilges M, Jouvion G, Glomski IJ, Mock M, Sirard JC, Goossens PL. 2013. In vivo germination of Bacillus anthracis spores during murine cutaneous infection. J. Infect. Dis. 207: 450-457.
29. Chen Z, Moayeri M, Purcell R. 2011. Monoclonal antibody therapies against anthrax. Toxins 3:1004-1019.
30. Chitlaru T, Altboum Z, Reuveny S, Shafferman A. 2011. Progress and novel strategies in vaccine development and treatment of anthrax. Immunol. Rev. 239:221-236.
31. Schneemann A, Manchester M. 2009. Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiol. 4:35-43.
32. Bannwarth L, Goldberg AB, Chen C, Turk BE. 2012. Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening. Chem. Biol. 19:875-882.
33. Panchal RG, Hermone AR, Nguyen TL, Wong TY, Schwarzenbacher R, Schmidt J, Lane D, McGrath C, Turk BE, Burnett J, Aman MJ, Little S, Sausville EA, Zaharevitz DW, Cantley LC, Liddington RC, Gussio R, Bavari S. 2004. Identification of small molecule inhibitors of anthrax lethal factor. Nat. Struct. Mol. Biol. 11:67-72.
34. Li F, Chvyrkova I, Terzyan S, Wakeham N, Turner R, Ghosh AK, Zhang XC, Tang J. 2012. Inhibition of anthrax lethal factor: lability of hydroxamate as a chelating group. Appl.Microbiol.Biotechnol. 94:1041-1049.
35. Dell'Aica I, Dona M, Tonello F, Piris A, Mock M, Montecucco C, Garbisa S. 2004. Potent inhibitors of anthrax lethal factor from green tea. EMBO Rep. 5:418-422.
36. Forino M, Johnson S, Wong TY, Rozanov DV, Savinov AY, Li W, Fattorusso R, Becattini B, Orry AJ, Jung D, Abagyan RA, Smith JW, Alibek K, Liddington RC, Strongin AY, Pellecchia M. 2005. Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl. Acad. Sci. U. S. A. 102:9499-9504.
37. Johnson SL, Pellecchia M. 2006. Structure-and fragment-based approaches to protease inhibition. Curr. Top. Med. Chem. 6:317-329.
38. Shoop WL, Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny JV, Felcetto T, Michael BF, Bansal A, Cummings RT, Cunningham BR, Friedlander AM, Douglas CM, Patel SB, Wisniewski D, Scapin G, Salowe SP, Zaller DM, Chapman KT, Scolnick EM, Schmatz DM, Bartizal K, Maccoss M, Hermes JD. 2005. Anthrax lethal factor inhibition. Proc. Natl. Acad. Sci. U. S. A. 102:7958-7963.